Expertise in
28
conditions

Dr. Robert G. Bociek

Hematology Oncology | Oncology | Hematology
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
Accepting New Patients
Expertise in
28
conditions
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Bociek is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Bociek is highly rated in 28 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bociek is currently accepting new patients.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NE
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Wellmark
  • HMO
  • POS

Locations

UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Biological, Drug
Study Drugs: Polatuzumab Vedotin, Rituximab, Hyaluronidase Human, Venetoclax
Study Phase: Phase 2
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Terminated
Publish Date: September 06, 2023
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Phase: Phase 2
View 3 Less Clinical Trials

56 Total Publications

CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma.
CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Similar Doctors
Julie M. Vose
Expertise in
36
conditions
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology

Unmc Physicians

111 N 175th St, 
Omaha, NE 
 (11.1 mi)
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Vose is highly rated in 36 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

Vijaya R. Bhatt
Expertise in
26
conditions
Dr. Vijaya R. Bhatt
Hematology Oncology | Hematology | Oncology
Expertise in
26
conditions
Dr. Vijaya R. Bhatt
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (0.1 mi)
402-559-4015
Experience:
16+ years
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

Vijaya Bhatt is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Bhatt has been practicing medicine for over 16 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhatt is currently accepting new patients.

James O. Armitage
Expertise in
22
conditions
Dr. James O. Armitage
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. James O. Armitage
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (0.1 mi)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

James Armitage is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Armitage is highly rated in 22 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy. Dr. Armitage is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bociek's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 13 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile